Skip to main content
VYNE Therapeutics Inc. logo

VYNE Therapeutics Inc. — Investor Relations & Filings

Ticker · VYNE ISIN · US92941V1008 US Manufacturing
Open in API
Filings indexed 607 across all filing types
Latest filing 2025-01-02 Director's Dealing
Country US United States of America
Listing US VYNE

About VYNE Therapeutics Inc.

https://vynetherapeutics.com/

VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company's primary objective is to address unmet medical needs by advancing a pipeline of novel drug candidates. VYNE's approach centers on innovating beyond traditional assumptions to find improved solutions for patients with complex inflammatory and immunological diseases.

Recent filings

Filing Released Lang Actions
Director's Dealing 2025
Director's Dealing
2025-01-02 English
Director's Dealing 2025
Director's Dealing
2025-01-02 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes a press release and a presentation related to positive Phase 1a clinical trial data for a drug candidate. The document does not contain full financial statements or detailed financial analysis but rather announces recent events and includes exhibits with a press release and presentation. The length is under 5,000 characters, and the content is typical of a current report announcing recent developments rather than a full financial report or earnings release. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2024-12-23 English
FORM S-8
Capital/Financing Update Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as equity incentive plans. It references the amendment and increase of shares under the 2023 Equity Incentive Plan and incorporates by reference prior filings including the Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The document is not a financial report itself but a registration statement related to equity compensation plans. This type of filing is a capital/financing update related to securities registration for employee plans, not an annual report, earnings release, or other report types. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-12-19 English
Director's Dealing 2024
Director's Dealing
2024-12-13 English
Director's Dealing 2024
Director's Dealing
2024-12-13 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.